When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CARA - Cara boosts enrollment in Korsuva dermatitis study extending timeline
Cara Therapeutics Inc.
Based the recommendation from the independent Data Monitoring Committee, Cara Therapeutics (NASDAQ:CARA) will increase the size of its Phase 2 dose-ranging clinical trial, KARE, evaluating oral Korsuva (CR845/difelikefalin) for the treatment of moderate-to-severe pruritis (itchy skin) in adult atopic dermatitis patients.
More news on: Cara Therapeutics, Inc., Healthcare stocks news,